TRVX.OL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 May 2023 @ 10:09):

Stats
Today's Volume	570 454
Average Volume	865 124
Market Cap	123.47M
EPS	NOK0 ( 2024-02-15 )
Next earnings date	( NOK0 ) 2024-05-09
Last Dividend	NOK0 ( N/A )
Next Dividend	NOK0 ( N/A )
P/E	-0.294
ATR14	NOK0.0540 (9.94%)

Volume Correlation

Long: 0.05 (neutral)

Short: -0.83 (strong negative)

Signal:(37.845) Neutral

Targovax ASA Correlation

10 Most Positive Correlations
ANDF.OL	0.969
EFUEL.OL	0.967
KMCP.OL	0.961
KOMPL.OL	0.957
ELIMP.OL	0.953
PLT.OL	0.948
NRC.OL	0.946
NOD.OL	0.943
VOW.OL	0.942
NEL.OL	0.941

10 Most Negative Correlations
EIOF.OL	-0.95
BORR.OL	-0.945
HAFNI.OL	-0.933
WWI.OL	-0.926
VAR.OL	-0.912
SNI.OL	-0.905
NKR.OL	-0.905
FROY.OL	-0.905
KAHOT.OL	-0.899
EQNR.OL	-0.898

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Targovax ASA Correlation - Currency/Commodity

-0.86
( strong negative )

-0.79
( moderate negative )

0.00
( neutral )

-0.79
( moderate negative )

-0.17
( neutral )

0.55
( weak )

Targovax ASA Financials

Annual	2022
Revenue:	NOK10.00M
Gross Profit:	NOK10.00M (100.00 %)
EPS:	NOK-2.30

Q4	2022
Revenue:	NOK10.00M
Gross Profit:	NOK10.00M (100.00 %)
EPS:	NOK-1.870

Q3	2022
Revenue:	NOK0
Gross Profit:	NOK0 (0.00 %)
EPS:	NOK-0.110

Q2	2022
Revenue:	NOK0
Gross Profit:	NOK0 (0.00 %)
EPS:	NOK-0.150

Financial Reports:

No articles found.

Targovax ASA

Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical trials for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen vaccines targeting mutant KRAS cancers. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.